A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants *Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB

The purpose of this study is to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of GEO-D02 DNA and MVA/HIV62B with and without B63521^11 gp120 and IHV01 gp120 Env proteins in healthy, HIV-uninfected adult participants.

Start Date01 Mar 2022

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+4]

NCT04977024 / RecruitingPhase 2

A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies

This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy.
GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from entering healthy cells. The immune system also grows new disease fighting T cells that can recognize and destroy infected cells. Giving GEO-CM04S1 after cellular therapy may work better in reducing the chances of contracting coronavirus disease 2019 (COVID-19) or developing a severe form of COVID-19 disease in patients with blood cancer compared to SOC mRNA SARS-CoV-2 vaccine.

Start Date27 Sep 2021

Sponsor / Collaborator

GeoVax, Inc.

NCT04639466 / CompletedPhase 1/2

Phase 1/2 Dose Escalation Study To Evaluate the Safety and Biologically Effective Dose of GEO-CM04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers

This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into synthetic MVA, which may be able to induce immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The purpose of the Phase 1 study is to determine the safety and the optimal dose of the GEO-CM04S1 vaccine.
The Phase 2 study is designed as a multi-center, double-blind, randomized, parallel, study to evaluate the safety profile of 2 dose levels of GEO-CM04S1 as a single booster shot to assess the immune response measured by the fold-increase in antibody against SARS-CoV-2 Spike protein at day 28 post-injection among healthy adult volunteers.

Start Date19 Nov 2020

Sponsor / Collaborator

GeoVax, Inc.

100 Clinical Results associated with GeoVax Labs, Inc.

0 Patents (Medical) associated with GeoVax Labs, Inc.

Literatures (Medical) associated with GeoVax Labs, Inc.

15 Sep 2023·Clinical Cancer Research

Abstract PO-005: Phase 1/2 study of Ad/PNP with fludarabine for the treatment of head & neck squamous cell carcinoma (HNSCC)

Author: Colevas, A. Dimitrios ; Henao, Camilo ; McKee, Kelly T. ; Rosenthal, Eben ; Schmitt, Nikki ; Parker, William B. ; Stallings, Madison ; Curry, Joseph ; Hong, Jeong S. ; Raymundo, Roan Courtney ; Sorscher, Eric J. ; Rab, Regina

AbstractThe project pursues clinical testing of a gene-based treatment for refractory malignancy of the head and neck. Background We are evaluating intratumoral nucleoside cleavage by E. coli purine nucleoside phosphorylase (PNP) as an experimental therapy for refractory solid tumors. The approach requires delivery of PNP transgene to tumor parenchyma followed by prodrug administration, and provides “bystander” killing by a very potent purine antimetabolite (F-Ade) generated intratumorally. F-Ade is 1,000-times more potent than fluorouracil, the chemotherapeutic produced by cytosine deaminase (CD; a first-generation construct used for tumor sensitization). PNP/F-Ade has been found to be superior to CD/fluorouracil by several laboratories. In a Phase 1 study (Rosenthal et al., Ann. Oncol.), antitumor activity was observed after IT injections of a recombinant adenovirus encoding PNP (Ad/PNP), followed by IV fludarabine phosphate (F-araAMP, a prodrug converted by PNP to F-Ade). Methods Patients in the present trial have RECIST 1.1 measurable HNSCC amenable to local injection and no other palliative treatment options. A single-arm protocol is being used to evaluate safety of repeat cycles of Ad/PNP and F-araAMP. Ad/PNP is injected intratumorally twice on Day 1 and once on Day 2, followed by infusion of F-araAMP on Days 3, 4, and 5 every 4 weeks for up to 5 cycles. Results Eight patients have been enrolled to date. There have been no dose limiting toxicities, no serious adverse events (SAEs) definitively attributable to treatment, and no AEs above grade 3 severity. Up to five cycles of Ad/PNP treatment have been administered without limiting sequelae. Intratumoral expression of PNP transgene by RT-PCR has been established in treated tumors. Other correlative endpoints are in process and will be discussed. One patient exhibited tumor volume reduction by approximately 21% (as judged by CT imaging) and did not increase during five months of treatment, consistent with clinically stable disease. Two other patients completed three months of Ad/PNP with stable disease by RECIST criteria during the treatment period. Another patient’s tumor (largest dimension 3.1 cm) demonstrated 25% decrease after one treatment cycle. Challenges have included: 1) complexity of distribution of agent into large volume tumors (e.g., >100 ml) with small volume of Ad/PNP, and 2) acute swelling of tumor tissue following intratumoral virus injection in two patients, consistent with inflammatory response and/or disease progression. Conclusions Administration of Ad/PNP is safe and feasible. Injections of large volume tumors remains a challenge. The strategy is also being considered for earlier-stage HNSCC with less tumor burden, including a role similar to neoadjuvant or cytoreductive radiotherapy in combination with checkpoint blockade inhibition. A muti-center trial is planned to define MTD and feasibility in smaller tumors.Citation Format: A. Dimitrios Colevas, Eric J. Sorscher, William B. Parker, Roan Courtney Raymundo, Jeong S. Hong, Regina Rab, Camilo Henao, Nikki Schmitt, Madison Stallings, Kelly T. McKee, Eben Rosenthal, Joseph Curry. Phase 1/2 study of Ad/PNP with fludarabine for the treatment of head & neck squamous cell carcinoma (HNSCC) [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-005.

01 Jan 2019·Computational and Structural Biotechnology JournalQ3 · BIOLOGY

Cryo-EM Reveals Architectural Diversity in Active Rotavirus Particles

Q3 · BIOLOGY

ArticleOA

Author: Casasanta, Michael ; McDonald, Sarah M ; Varano, A Cameron ; Hauser, Mary ; Dearnaley, William J ; Kelly, Deborah F

Rotavirus is a well-studied RNA virus that causes severe gastroenteritis in children. During viral entry, the outer layer of the virion is shed, creating a double-layered particle (DLP) that is competent to perform viral transcription (i.e., mRNA synthesis) and launch infection. While inactive forms of rotavirus DLPs have been structurally characterized in detail, information about the transcriptionally-active DLP remains limited. Here, we used cryo-Electron Microscopy (cryo-EM) and 3D image reconstructions to compare the structures of internal protein components in transcriptionally-active versus inactive DLPs. Our findings showed that transcriptionally-active DLPs gained internal order as mRNA synthesis unfolded, while inactive DLPs remained dynamically disordered. Regions of viral protein/RNA constituents were analyzed across two different axes of symmetry to provide a more comprehensive view of moving components. Taken together, our results bring forth a new view of active DLPs, which may enable future pharmacological strategies aimed at obliterating rotavirus transcription as a therapeutic approach.

02 Sep 2018·Expert Review of VaccinesQ2 · MEDICINE

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine

Q2 · MEDICINE

Author: Robinson, Harriet L. ; Marzi, Andrea

A review discussing ebola virus prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine.

News (Medical) associated with GeoVax Labs, Inc.

25 Oct 2023

·www.biospace.com

GeoVax to Participate in Upcoming November 2023 Investor and Industry Events

ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in four upcoming investor and industry events during November. Event details are as follows: Emerging Growth Conference, November 1-2, 2023, Virtual Date/Time: November 2, 2023 at 3:55 p.m. ET Title: GeoVax Corporate Update Speaker: David Dodd, Chairman & CEO, GeoVax Labs, Inc. For more information and to register to attend the GeoVax Presentation, please visitEmerging Growth Conference. BIO-Europe, November 6-8, 2023, Munich, Germany Senior GeoVax management will host one-on-one meetings with registered attendees. For more information, please visit Bio-Europe. If interested in meeting with management at this event, please contact the company through the conference portal, or directly at info@geovax.com. Vaccines Summit 2023, November 13-15, 2023, Boston, MA Date/Time: November 14, 2023 at 8:00 a.m. ET Session Title: MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models Speaker: Mukesh Kumar, PhD, Associate Professor, Department of Biology, Georgia State University For more information on the conference, please visitVaccines Summit 2023. World Vaccine Congress, West Coast, November 27-30, 2023, Santa Clara, CA Date/Time: November 28, 2023 at 4:20 p.m. PT Session Title: COVID-19 Vaccines for immunocompromised patients Speaker: Don Diamond, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center Date/Time: November 30, 2023 at 1:40 p.m. PT Session Title: Design and evaluation of vaccines against hemorrhagic fevers using the MVA-VLP platform Speaker: Jason Comer, PhD, Associate Professor, Department of Microbiology and Immunology, University of Texas Medical Branch For more information on the conference, please visitWorld Vaccine Congress, West Coast. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: Company Contact: Investor Relations Contact: Media Contact: info@geovax.com paige.kelly@sternir.com sr@roberts-communications.com 678-384-7220 212-698-8699 202-779-0929

VaccinePhase 2Immunotherapy

23 Jun 2023

·www.prnewswire.com

Assessment of Human DNA Vaccine Markets to 2028 by Mode of Administration, Application, End-user and Region

DUBLIN, June 23, 2023 /PRNewswire/ -- The "Human DNA Vaccine Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Mode of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application, By End User, By Region and Competition" report has been added to ResearchAndMarkets.com's offering. The global human DNA vaccine market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing to the growing prevalence of cancer and infectious diseases in humans. An increase in the number of antibiotic-resistant pathogens is further expected to drive the growth of the human DNA Vaccine Market. The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion. Rise in Prevalence of Different Diseases Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle. Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV. Increase in Number of Antibiotics Resistant Pathogens Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens. Some multi and resistant bacteria called "superbugs" that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market. Growth in R&D for DNA Vaccine Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market. Recent Developments ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity. The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D. Report Scope In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below. Human DNA Vaccine Market, by Mode of Administration Intramuscular Subcutaneous Intradermal Others Human DNA Vaccine Market, by Application Oncology Tuberculosis HIV Human Papillomavirus Others Human DNA Vaccine Market, by End-user Hospitals & Clinics Biotechnology & Pharmaceutical Companies Academic & Research Institutions Others Human DNA Vaccine Market, by Region North America Europe Asia-Pacific South America Middle East & Africa Competitive Landscape Detailed analysis of the major companies present in Global Human DNA Vaccine market. A selection of companies mentioned in this report includes: BOEHRINGER INGELHEIM GmbH (Merial) ELI-LILLY (Novartis Animal Health) Gene One Life Science GEOVAX LABS, INC Inovio Pharmaceuticals (VGX Animal Health) Genexine, Inc. VIATRIS INC. (Rottapharm Biotech) Takara Holdings (Takara Bio) ZOETIS INC. (Fort dodge Animal Health) Zydus Lifesciences Limited For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

VaccineClinical StudyEmergency Use AuthorizationDrug Approval

22 Jun 2023

·www.prnewswire.com

Global Cancer Vaccine Partnering Terms and Agreements Analysis Report/Directory 2023: Access Over 350 Cancer Vaccine Deals - Disclosed Headlines, Upfronts, Milestones and Royalties

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Cancer Vaccine Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 350 cancer vaccine deals. Trends in cancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer vaccine partnering contract documents Top cancer vaccine deals by value This report provides details of the latest cancer vaccine agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review cancer vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering cancer vaccine partnering deals. The report presents financial deal term values for cancer vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the cancer vaccine partnering field; both the leading deal values and most active cancer vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 350 online deal records of actual cancer vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of cancer vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading cancer vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer vaccine dealmaking with a brief summary followed by a comprehensive listing of cancer vaccine deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific cancer vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by cancer vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products. Key benefits In-depth understanding of cancer vaccine deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual cancer vaccine contracts entered into by leading biopharma companies Identify most active cancer vaccine dealmakers since 2010 Insight into terms included in a cancer vaccine partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies In Global Cancer Vaccine Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sale sand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned 2A 3D Medicines A*STAR Bioprocessing Technology Institute Aura Biosciences Averion AV Therapeutics Beth Israel Deaconess Medical Center BGI CureLab Oncology CureVac Cyplasin Biomedical CYTLIMIC Daiichi Sankyo Dainippon Sumitomo Pharma Dalton Pharma Services Exiqon ExpreS2ion Biotechnologies Federal Ministry of Education and Research (BMBF) Flaskworks Georgia Health Sciences University GeoVax German Cancer Research Center Hookipa Pharma Human Vaccines Project iBio Icahn School of Medicine at Mount Sinai Ichor Medical Systems Leukaemia & Lymphoma Research LG Life Sciences Ligand Pharmaceuticals Massachusetts Life Sciences Center Mayo Clinic National Research Council Canada National Surgical Adjuvant Breast and Bowel Project OncoQR OncoSec Medical Oncotherapy Science PsiOxus Therapeutics Pulmotec PX Biosolutions Qiagen Radboud University Nijmegen Medical Centre Selecta Biosciences Selexis Sellas Clinicals Holding Seres Therapeutics Telormedix Teva Pharmaceutical Industries VGX International Vinnova ViroMed Vivalis VLP Therapeutics VLST Corporation Y-mAbs Therapeutics Yale University Yamaguchi University For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Vaccine

100 Deals associated with GeoVax Labs, Inc.

100 Translational Medicine associated with GeoVax Labs, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Purine nucleoside phosphorylase gene therapy(The University of Alabama) ( PNP )	Recurrent Head and Neck Carcinoma More	Phase 2 Clinical
GOVX-B11	HIV Infections More	Phase 2
COH04S1 ( SARS-CoV-2 N protein x SARS-CoV-2 S protein )	Multiple Myeloma More	Phase 2
GEO-D02	HIV Infections More	Phase 1
GEO-MVA-MUCI	Solid tumor More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis